common to all fibrotic diseases is the activation of ECM-producing myofibroblasts, which are the key mediators of fibrotic tissue remodeling 4, 5 . For example, the left-ventricular hypertrophy that accompanies chronic hypertension is caused by an abnormal accumulation of collagen and other ECM components in the extracellular space. This reactive and progressive interstitial fibrosis contributes to myocardial stiffness and, ultimately, ventricular dysfunction, and it is believed to result from the persistent activation of cardiac myofibroblasts. Liver cirrhosis caused by chronic hepatitis C virus (HCV) infection, alcohol abuse or nonalcoholic steatohepatitis (NASH) is similarly induced by activated myofibroblasts 1 . In the liver, excessive collagen deposition distorts normal tissue architecture, leading to hepatocellular dysfunction and increased hepatic resistance to blood flow, which cause hepatic insufficiency and portal hypertension. Because ECMsecreting myofibroblasts are central to the pathogenesis of all fibrotic diseases, fibrosis research has focused on elucidating the molecular and immunological mechanisms that initiate, maintain and terminate the differentiation of quiescent fibroblasts into actively proliferating, ECM-producing myofibroblasts.
It is now clear that many elements of the innate and adaptive immune response participate in the differentiation and activation of fibroblasts ( Fig. 1) . In this Review, we describe some of the important mechanisms that contribute to the progression of fibrosis. We also present experimental findings from several different model systems, with the goal of identifying common pathways of fibrosis that could be targeted to facilitate the development of broadly effective antifibrotic drugs. Finally, we discuss some of the major obstacles in antifibroticdrug development and highlight a few of the important pathways of fibrogenesis that have progressed to clinical testing.
Innate immunity and fibrosis
Acute inflammatory reactions play an important part in triggering fibrosis in many different organ systems. For example, in bleomycininduced pulmonary fibrosis and carbon tetrachloride-induced liver fibrosis, brief exposure to these drugs causes epithelial-cell apoptosis and hepatocyte necrosis, respectively, activating an inflammatory wound-healing response that can lead to a temporary excess in deposition of ECM components in the affected tissues 6, 7 . Low-grade but persistent inflammation is also thought to contribute to the progression of fibrosis in cardiovascular disease and hypertension. Indeed, in many fibrotic disorders, a persistent inflammatory trigger is crucial to the activation of the wound-healing program that leads to fibrosis. Consequently, removal of the inflammatory trigger is the most straightforward way to halt the progression of tissue remodeling and allow the normal tissue architecture to be restored after injury, as has been observed in individuals with chronic hepatitis B infection who are treated with entecavir, a highly effective oral antiviral drug. This may be easy to accomplish when the tissue-damaging mechanism is known, but in many fibrotic disorders, the tissue-damaging irritant is either unknown or cannot be easily eliminated. In this case, researchers have focused on pinpointing the innate and adaptive mechanisms that control inflammation, with the goal of identifying key mediators that could be targeted to attenuate fibrosis.
Innate wound-healing mechanisms initiate the fibrotic response.
The coagulation response is the first wound-healing mechanism activated after injury. When the endothelium is damaged, circulating platelets are activated upon encountering exposed collagen and von Willebrand factor in the subendothelial layer 8 . Coagulation factor II (prothrombin) is also proteolytically cleaved to form thrombin. Thrombin, in turn, functions as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, which helps platelets clump together to form the fibrin clot that ensures quick hemostasis. Activated platelets also release growth factors such as platelet-derived growth factor (PDGF), a potent chemoattractant for inflammatory cells, and transforming growth factor-β1 (TGF-β1), which stimulates ECM synthesis by local fibroblasts 9 . Consequently, any prolonged disturbance in the coagulation cascade can lead to fibrosis 10 . For example, a recent study demonstrated that activated coagulation factor X (FXa) contributes to fibrosis after acute lung injury by inducing myofibroblast differentiation 11 . The authors showed that bleomycininduced pulmonary fibrosis could be inhibited in mice when FXa was neutralized. The coagulation response is also believed to be a major driver in the pathogenesis of liver fibrosis. In addition to its role in the coagulation cascade, thrombin can directly promote fibrosis by inducing production of chemokine (C-C motif) ligand 2 (CCL2) and by signaling through protease-activated receptors expressed on liver fibroblasts (hepatic stellate cells) 12 . In support of this hypothesis, antagonists of protease-activated receptor 1 and anticoagulant drugs have each been shown to protect against experimental liver fibrosis in mice 13, 14 . However, although the coagulation cascade can be an important initiator of fibrosis, deficiencies in the clotting pathway have also been shown to contribute to fibrosis. Procoagulant deficiencies are common in patients with cirrhosis and portal hypertension. Here, obliterative lesions in the portal and hepatic veins develop in response to microthrombi, which cause tissue ischemia, endothelialcell death and fibrosis through parenchymal extinction 15 . Together, these findings illustrate how disturbances in the coagulation cascade can substantially contribute to the development of progressive fibrotic disease.
Inflammatory myeloid cells have a role in fibrosis.
In addition to activating the coagulation cascade, platelets and damaged epithelial and endothelial cells release a variety of chemotactic factors that recruit inflammatory monocytes and neutrophils to the site of tissue damage (Fig. 2) . These circulating myeloid cells respond to a gradient of CCL2 and are recruited to damaged tissues, where they differentiate into macrophages that phagocytose the fibrin clot and cellular debris. ECM fragments, including hyaluronan, have also been shown to be important drivers of fibrosis by stimulating chemokine and proinflammatory cytokine production by inflammatory monocytes and macrophages 16 . Neutrophils are also recruited quickly after injury and participate in removal of tissue debris and the killing of invading bacteria. Although the recruitment of inflammatory monocytes and neutrophils at the site of tissue injury is important for the wound-healing process, these cells also secrete a variety of 17 . Other studies have identified a similar profibrotic role for neutrophils in bleomycin-and hypersensitivity pneumonitis-induced pulmonary fibrosis in mice, and possibly in IPF 18 . It has also been suggested that liver dendritic cells have a role in the development of liver fibrosis, by promoting inflammation and activating hepatic stellate cells 19 . Thus, limiting the proinflammatory activity of innate myeloid-lineage cells might prove highly beneficial in a variety of chronic inflammatory and fibrotic diseases.
Innate inflammatory mediators regulate fibrosis. Various growth factors and cytokines secreted by innate inflammatory cells (including macrophages, neutrophils, mast cells and eosinophils) have emerged as potential targets for antifibrotic therapy. Tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), in particular, have been identified as important targets in a variety of fibrotic diseases 20 . Mice that overexpress TNF-α or IL-1β in the lung develop highly progressive pulmonary fibrosis 21, 22 . Studies have also shown an essential role for TNF-α in the development of silica-and bleomycin-induced pulmonary fibrosis in mice 23, 24 . In support of these experimental findings, patients with idiopathic or systemic sclerosis-associated pulmonary fibrosis have high levels of TNF-α 25 . TNF-α has also been shown to play a crucial part in radiation-induced fibrosis, Crohn's diseaseinduced intestinal fibrosis, CCL4-and cholestasis-induced liver fibrosis and NASH [26] [27] [28] . Consequently, clinical trials have recently been initiated to evaluate whether TNF pathway inhibitors such as etanercept or infliximab could be beneficial for the treatment of pulmonary fibrosis and other fibrotic diseases 29 . Similarly to the TNF-α studies, other studies have documented profibrotic activity for IL-1β
and NALP3/ASC inflammasome signaling in macrophages 30 . Pulmonary fibrosis induced by bleomycin and silica, liver fibrosis in hypercholesterolemic mice, renal interstitial fibrosis resulting from unilateral ureteric obstruction and cardiovascular fibrosis after myocardial infarction are all reduced in IL-1β-deficient mice [31] [32] [33] . Like TNF-α, IL-1β is a potent proinflammatory mediator that exacerbates parenchymal-cell injury. It also induces epithelial-mesenchymal transition (EMT) and myofibroblast activation through a TGF-β1-mediated mechanism 34 , confirming that it functions as a potent upstream driver of fibrosis. IL-1β and TNF-α also increase expression of IL-6, which shows autocrine growth-factor activity in fibroblasts. IL-6 is an important mediator of fibrosis in diffuse systemic sclerosis, liver fibrosis after CCL4 exposure and fibrosis in chronic cardiac allograft rejection 35, 36 . Thus, many innate proinflammatory cytokines have crucial roles in the pathogenesis of fibrosis.
TGF-β1 has both anti-inflammatory and profibrotic activity.
Macrophages that appear early in the wound-healing response are also major producers of TGF-β, which is, indisputably, one of the key drivers of fibrosis. TGF-β production correlates with the progression of liver, lung, kidney, skin and cardiac fibrosis, and inhibition of the TGF-β1 signaling pathway has been shown to reduce the development of fibrosis in many experimental models. In addition to its role as a profibrotic cytokine that can directly induce the differentiation of fibroblasts into collagen-secreting myofibroblasts, TGF-β1 is now widely described as a multifunctional cytokine with broad modulatory activities that affect numerous important biological pathways. These include pathways involved in the regulation of embryogenesis, immunity, carcinogenesis, cell proliferation and migration, wound healing, inflammation and fibrosis, among others 37 . Studies have suggested that the cellular source of TGF-β1 dictates its activity, with TGF-β1 derived from macrophages generally showing woundhealing and profibrotic activity and TGF-β1 secreted from CD4 + T regulatory cells (T reg cells) functioning as an anti-inflammatory and antifibrotic mediator 38 . Mice that are deficient in TGF-β1 develop numerous autoimmune disorders and are more susceptible to cancer. Therefore, it remains unclear whether antagonism of the TGF-β1 signaling pathway will prove beneficial in humans, as patients with progressive fibrosis are likely to require prolonged antifibrotic therapy.
Alternatively activated M2 macrophages suppress fibrosis.
A unique functional subset of macrophages, called M2 or alternatively activated macrophages, has also been implicated in the pathogenesis of fibrosis 39 . Gordon and his colleagues first noted that macrophages activated with IL-4 (or IL-13) develop an alternative activation state that is distinct from that of classically activated macrophages (M1) induced by interferon-γ (IFN-γ) 40 . In vitro and in vivo studies in mice have shown that this phenotype is characterized by elevated expression of the mannose receptor (CD206), chitinase-3-like protein-3 (Chi3l3, also known as Ym1), resistin-like molecule-α (Relm-α, also known as FIZZ-1), major histocompatibility complex class II antigens and the enzyme arginase-1 (Arg1). Expression of Arg1 by M2 cells is of particular interest because this enzyme controls l-proline production, which is required for collagen synthesis by activated myofibroblasts 41 . M2 cells have also been implicated in the development of T helper type 2 (T H 2) effector responses, production of fibrogenic cytokines, suppression of M1 responses and recruitment of fibrocytes 42, 43 . Because they are commonly observed during the peak of the profibrotic immune response, M2 macrophages have been hypothesized to be important inducers of wound healing and fibrosis. However, mechanistic studies conducted with LysM Cre IL-4Rα -/flox mice, in which Cre-mediated recombination results in deletion of the IL-4Rα chain in the myeloid cell lineage, including in M2 cells, have demonstrated that M2 macrophages are not required for the development of T H 2 responses or liver fibrosis following infection with Schistosoma mansoni 44 . In fact, related studies done in mice with a conditional Arg1 deficiency suggested that Arg1-expressing M2 cells are required for the suppression and resolution of fibrosis 45 . These later experiments suggested that M2 cells compete with T H 2 cells and fibroblasts for l-arginine, which is required for the production of polyamines and l-proline, which regulate cell growth and collagen synthesis, respectively. The inhibitory activity of M2 cells is also consistent with studies showing them to be important inducers of T reg cells 46 , which have also been implicated in the suppression of fibrosis. Thus, rather than promoting fibrosis, M2 cells seem to exploit multiple mechanisms to inhibit ECM synthesis by myofibroblasts. Given this modified view of the role of M2 macrophages, it will be important to investigate whether M2 cells have a similar inhibitory role in other models of fibrosis. These findings suggest that M2 cells could be exploited to ameliorate fibrotic disease. Indeed, drugs that modulate the activation status of macrophages could emerge as a general therapeutic strategy to treat fibrosis. For example, peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ are induced in inflammatory macrophages, and endogenous and synthetic ligands that engage these receptors have been shown to inhibit the development of fibrosis by inducing the differentiation of alternatively activated macrophages that decrease proinflammatory cytokine production by M1 cells 47, 48 . PPAR ligands also directly inhibit fibroblast activation induced by TGF-β1 (ref. 49) . In support of these observations, PPAR-α and PPAR-γ activators have proven efficacious in a variety of experimental models of fibrosis, including hypertension-induced cardiac fibrosis, bile duct ligationinduced liver fibrosis, unilateral ureteral obstruction-induced renal interstitial fibrosis and bleomycin-induced pulmonary fibrosis [50] [51] [52] [53] . The M2 macrophages that develop spontaneously during helminth infection have also been shown to reduce inflammation and slow the progression of liver fibrosis 44, 45 . Thus, the conditional IL-4Rα-and Arg1-deficient mice described above will be important tools to further investigate the therapeutic potential of M2 cells in fibrotic disease.
Other innate myeloid-lineage cells have roles in fibrosis.
Although it is widely recognized that monocytes, macrophages and neutrophils have important roles in the progression and resolution of fibrosis 39 , other myeloid-lineage cells (such as mast cells, eosinophils and basophils) have also been implicated in the pathogenesis of fibrosis in multiple organ systems and are viewed as potential therapeutic targets. For example, studies in mice have identified mast cells as inducers of systemic sclerosis, renal fibrosis after kidney transplantation and left-ventricular fibrosis in hypertensive hearts. Mechanistic studies in rats have suggested that mast cells promote fibrosis by recruiting inflammatory leukocytes and by producing profibrotic mediators 54 . Eosinophils seem to function in a similar fashion and are considered to be important sources of TGF-β1 and IL- 13 (refs. 55,56) . Although eosinophils have been most commonly associated with the development of pulmonary fibrosis 57 , increased numbers of eosinophils have also been linked with the activation of myofibroblasts in skin and liver fibrosis as well as idiopathic retroperitoneal fibrosis 55, 58 . Bronchoalveolar-lavage eosinophilia has also been identified as a predictive biomarker of progressive lung disease in IPF and pulmonary fibrosis associated with collagen vascular disorder 59 . Finally, although basophils have a less clear role in the development of fibrosis than the other myeloid-cell populations, they have been implicated in the pathogenesis of myelofibrosis and are frequently found in greater numbers in patients with interstitial lung disease 60 . Basophils are also thought to be an important source of type 2 cytokines, suggesting that they might serve as important drivers of IL-4-and/or IL-13-dependent fibrosis.
Adaptive immunity and fibrosis
T H 17-type immunity is proinflammatory and profibrotic. CD4 + T cells are divided into unique subsets on the basis of the cytokines they secrete and their distinct functional abilities (Fig. 3 ). The CD4 + T H 17 cell subset that expresses the proinflammatory cytokine IL-17A is emerging as an important driver of fibrosis. IL-17A expression has been implicated in the pathogenesis of pulmonary fibrosis 61 , chronic allograft rejection 62 , fibrosis in orthotopic lung transplantation 63 , myocardial fibrosis 64 and hepatitis-induced hepatic fibrosis 65 . In many cases, IL-17A expression is associated with persistent neutrophilia 66 , and it has been suggested that exaggerated neutrophil recruitment contributes to the development of tissue damage and fibrosis by inducing apoptosis in vascular endothelial cells 67 . Neutrophil recruitment is also an important predictor of early mortality in IPF patients 68 . Mechanistic studies investigating the IL-17 pathway of fibrosis in mice have identified the proinflammatory cytokines IL-1β and IL-23 as important upstream initiators of profibrotic T H 17 responses 61, 69 . A link between IL-17A and TGF-β1 has also been identified 61 . In addition to its role in promoting neutrophilic inflammation, IL-17A has been shown to directly induce expression of matrix metalloproteinase-1 in primary human cardiac fibroblasts 70 , suggesting that IL-17A promotes fibrosis by both exacerbating the upstream inflammatory response and regulating the downstream activation of fibroblasts. Together, these data identify the IL-1β-IL-17A-TGF-β1 cytokine axis as an important pathway in inflammation-driven fibrosis.
T H 2-type immunity is a potent driver of progressive fibrosis.
Numerous studies have suggested that the type 2 cytokine response is a key driver of progressive fibrosis 71 . T H 2 responses are defined npg r e v i e w 1 0 3 2 VOLUME 18 | NUMBER 7 | JULY 2012 nature medicine by the production of IL-4, IL-5 and IL-13 (ref. 72) , and although all three have been linked to the development of fibrosis 55, 73, 74 , IL-13 has emerged as a dominant mediator of fibrotic tissue remodeling in several experimental and natural models of fibrosis 74 . IL-13 production has been implicated in the development of fibrosis in chronic asthma 75 , IPF 76 , models of experimental lung fibrosis 77 , systemic sclerosis 78 , atopic dermatitis-induced skin fibrosis 79 , radiationinduced fibrosis 80 , fibrosis associated with ulcerative colitis 81 and liver fibrosis resulting from persistent infections and NASH 82, 83 . Mechanistically, IL-13 has been hypothesized to induce fibrosis by stimulating the production and activation of TGF-β 84 . However, other studies have suggested that IL-13 can promote fibrosis independently of TGF-β 85, 86 by directly activating the synthetic and proliferative properties of fibroblasts, epithelial cells and smooth-muscle cells 87, 88 . Consequently, unlike IL-17A-which seems to promote fibrosis indirectly by inducing tissue damage and inflammation-IL-13 and TGF-β show direct fibrotic activity. T H 2 cells that produce IL-13 and T reg cells that express TGF-β are also known to inhibit T H 17 responses 89 , suggesting dual roles for IL-13 and TGF-β in the wound-healing response, as both cytokines suppress inflammation while promoting fibrosis. The profibrotic activity of IL-13 is controlled by the abundance of the IL-13Rα1 signaling receptor and IL-13Rα2 decoy receptor expressed on important target cells such as myofibroblasts 90, 91 . When decoy receptor expression is low or absent, IL-13-dependent fibrosis is exacerbated 92 . However, mice deficient in IL-13Rα2 are more resistant to IL-1β-and IL-17-driven inflammation, probably because of the enhanced IL-13 activity 89 , suggesting that IL-13Rα2 functions as a key regulator of both T H 17-mediated inflammation and T H 2-driven fibrosis 93 .
T H 1-type immunity shows antifibrotic activity. Numerous studies have suggested that T H 1 effector T cells, defined by their production of IFN-γ, have antifibrotic activity [94] [95] [96] . IFN-γ-producing natural killer and natural killer T cells have also been shown to have similar roles 97, 98 . Mechanistically, IFN-γ is believed to inhibit fibrosis, at least in part, by antagonizing the profibrotic activity of TGF-β1. IFN-γ inhibits the TGF-β-induced phosphorylation of the signal transducer Smad3 and subsequent activation of TGF-β-responsive genes 99 . IFN-γ also acts through a pathway dependent on Janus-associated kinase (Jak1) and the transcription factor Stat1 and induces expression of Smad7, which can prevent the interaction of Smad3 with the TGF-β receptor, thus further attenuating TGF-β-induced signaling. IFN-γ also directly inhibits fibroblast proliferation, TGF-β1-induced expression of the genes encoding procollagen I and procollagen III, and collagen synthesis in activated myofibroblasts 100 . IFN-γ also prevents the T H 2 cytokine-induced differentiation of CD14 + peripheral blood monocytes into fibroblast-like cells called fibrocytes, which are believed to participate in the development of fibrosis in many organ systems 101 . Finally, by virtue of its ability to stimulate IFN-γ production in T H 1 and natural killer cells, IL-12 has shown similar antifibrotic activity in vivo in mice 71, 102 . But despite an abundance of in vitro and in vivo evidence supporting an antifibrotic role for T H 1-type immunity, clinical studies investigating the therapeutic potential of IFN-γ in the treatment of IPF, systemic sclerosis and other fibrotic disorders have so far been mostly disappointing 103 .
T reg cells either suppress or promote fibrosis. T reg cells are induced in a variety of fibrotic diseases, but their role in tissue fibrogenesis is less clear than that of some of the other subsets of T H cells. Foxp3-expressing T reg cells are important producers of immunosuppressive cytokines that control T reg cell function, such as IL-10 and TGF-β1. Thus, one might predict that if T reg cells were present in sufficient numbers, they would inhibit progressive fibrotic disease by negatively regulating the inflammatory response that drives ECM deposition. Indeed, several groups exploring the mechanisms of fibrosis have documented a suppressive role for T reg cells in tissue fibrogenesis. T reg cells have been linked to the amelioration of fibrosis in IPF 104 , dystrophic mouse muscle 105 , cardiovascular disease 106 , chronic graft-versus-host disease-induced lupus nephritis 107 and chronic HCV-and HIV-induced liver fibrosis 108 . One study has suggested that T reg cells protect mice from fibrosis by secreting IL-10 (ref. 38 ). However, T reg cells are also an important source of TGF-β1, with at least a few studies demonstrating that TGF-β-producing T reg cells induce rather than inhibit fibrosis 109, 110 . Therefore, it remains uncertain whether T reg cells can be effectively exploited to ameliorate progressive fibrotic disease. It is unclear why T reg cells would have antifibrotic activity in some situations and profibrotic activity in others, but the development and recruitment of T reg cells relative to other effector T cell populations is likely to have a decisive role. It also seems plausible that T reg cells could suppress T H 17-and T H 2-driven fibrosis but exacerbate TGF-β1-dependent fibrosis.
Intrinsic, autocrine and epigenetic mechanisms regulate fibrosis Mechanical modifications to the ECM and cell-intrinsic changes in fibroblasts and epithelial cells have also been shown to contribute to the progression of fibrosis by maintaining the activation of key fibrogenic pathways.
Mechanisms that perpetuate myofibroblast activation. The Wnt-β-catenin signaling pathway, which regulates cell growth and is intimately involved in tumorigenesis, is constitutively activated in alveolar epithelial type II (ATII) cells in mouse models of pulmonary fibrosis and in patients diagnosed with IPF and chronic obstructive pulmonary disease 111 . Activation of Wnt-β-catenin signaling has also been reported in kidney, liver, skin and cardiac fibrosis 112, 113 . Mechanistically, Wnt-1-inducible signaling protein 1 (WISP-1) has been shown in mice to increase the proliferation of ATII cells, promote EMT in the lung and kidney and mediate TGF-β1-driven renal fibrosis 114 (Fig. 4) . WISP-1 also increases the synthesis of ECM components in mouse and human lung fibroblasts and regulates activation of hepatic stellate cells in the liver 115 . Blocking studies demonstrated that bleomycin-induced pulmonary fibrosis is highly dependent on the Wnt-1 pathway 116 . Thus, Wnt signaling has emerged as a potential therapeutic target for IPF and several other chronic fibrotic disorders.
As tissues become more fibrotic, the increased tissue stiffness and decreased elasticity result in mechanical stress, which has been shown to exacerbate tissue injury and perpetuate the activation of local fibroblasts expressing α-smooth muscle actin (α-SMA) 117 . Two recent in vitro studies in mouse and porcine cells have suggested that mechanical stress contributes to aberrant wound healing and fibrosis by inducing EMT in alveolar type II epithelial cells via a mechanism driven by TGF-β1, Wnt-β-catenin and hyaluronan 118, 119 . Fibroblasts that are activated as a result of increased tissue or substrate stiffness also seem to maintain their activated phenotype when returned to healthy 'soft' tissues 120 , suggesting that mechanical sensing by fibroblasts can permanently alter their behavior in favor of a fibrotic phenotype. Indeed, it has been suggested that the differentiation of fibroblasts into ECM-producing myofibroblasts is controlled by the combined actions of IL-1β, TGF-β1 and mechanical tension 121 .
Increased compression, shear forces and hydrostatic pressures associated with portal hypertension and vascular remodeling can also perpetuate myofibroblast activation.
Epigenetic modifications in fibroblasts also contribute to the pathogenesis of fibrosis by stably altering the activation status of myofibroblasts. A recent genome-wide methylation scan of fibroblasts revealed several DNA methylation modifications that were unique to collagen-secreting myofibroblasts obtained from fibrotic mouse kidneys 122 . One of the modifications contributed to the epigenetic silencing of Rasal1 (encoding a suppressor of the Ras oncoprotein), which increased Ras activity and led to spontaneous, growth factor-independent proliferation of fibroblasts. These findings were important because they suggested that intrinsic changes in fibroblasts could lead to the uncontrolled expansion of myofibroblasts seen in some cancers. They also provided a new molecular explanation for the sustained and heritable activation of fibroblasts that is often seen in IPF and other highly progressive fibrotic diseases. On the basis of these observations, it may be predicted that the targeted repression of known antifibrotic genes by hypermethylation could contribute to the development of fibrosis, as was recently documented in IPF 123 . DNA methyltransferase inhibitors were found to reverse epigenetic modifications and protect mice from pulmonary fibrosis 124 . Therefore, because epigenetic modifications seem to be reversible, they could emerge as important targets for antifibrotic therapy.
Endoplasmic reticulum stress and the unfolded protein response.
Intrinsic mechanisms that contribute to cell death have also been hypothesized to regulate the progression of fibrosis. Endoplasmic reticulum (ER) stress leading to apoptosis of key structural cells, such as epithelial cells, endothelial cells and hepatocytes, is believed to be an important driver of fibrosis. For example, excess accumulation of unfolded or misfolded proteins in the ER activates cellular stress pathways. The stress response, in turn, activates a complex counterresponse, which is typically protective for the cell. However, if the counter-response is delayed, inadequate or associated with substantial mitochondrial dysfunction, it can lead to apoptosis and sustained activation of the wound-healing response. Hepatocyte apoptosis driven by ER stress is believed to play a major part in the pathogenesis of liver fibrosis in NASH 125 . ER stress leading to apoptosis in alveolar epithelial cells is also thought to have a key role in sporadic IPF 126, 127 . Therefore, a better understanding of the mechanisms that induce ER stress or lead to its resolution could reveal new strategies to prevent or treat progressive fibrotic disease.
Telomere shortening in mesenchymal cells promotes injury leading to fibrosis. Telomere shortening has been hypothesized to be an important contributor to the development of adult-onset and familial forms of pulmonary fibrosis 128, 129 . Indeed, circulating peripheral leukocytes with shortened telomeres are found in a large percentage of sporadic, familial and idiopathic cases of pulmonary fibrosis. This shortening has been attributed to mutations in the gene encoding telomerase reverse transcriptase (TERT), an enzyme crucial to the maintenance of telomere length in adult stem cells [130] [131] [132] . Alveolar type 2 cells and lung-resident mesenchymal stem cells express telomerase, and mutations in this enzyme have been shown to contribute to their premature death, resulting in decreased lung regeneration after injury. Telomerase-null mice also show compromised lung alveolar integrity and decreased myofibroblast differentiation as a result of telomere shortening 133, 134 . Profibrotic mediators, such as npg r e v i e w 1 0 3 4 VOLUME 18 | NUMBER 7 | JULY 2012 nature medicine TGF-β1 and reactive oxygen intermediates, also participate in telomere shortening 135, 136 , suggesting that a vicious cycle of profibrotic-mediator production, impaired telomerase activity and increased senescence of stem cells and/or AT2 cells contributes to the pathogenesis of fibrosis. Nevertheless, studies with TERT-deficient mice have raised questions about whether TERT has only a protective role in fibrosis, as telomerase activity was found to be necessary for development of bleomycininduced pulmonary fibrosis in mice 137 .
MicroRNAs regulate fibroblast growth and activation. MicroRNAs (miRNAs) include a broad class of small evolutionarily conserved noncoding RNAs that have important roles in a variety of pathophysiological processes by blocking translation or promoting degradation of complementary target mRNAs. Although unique subsets of miRNAs have been identified in various fibrotic diseases, a much smaller subset of miRNAs have emerged as key regulators of the fibrotic process. For example, miR-21 is expressed in the lungs of individuals with IPF, and mice treated with miR-21 antisense probes were protected from bleomycin-induced pulmonary fibrosis 138 and cardiac fibrosis induced by pressure overload 139 . Mechanistically, miR-21 is thought to promote fibrosis by regulating TGF-β1 and MAP kinase signaling in activated myofibroblasts 138, 139 . miR-21 suppresses several tumor suppressor genes, suggesting that MIR21 may also function as an oncogene. miR-21 also operates as an antiapoptotic factor in tumor cells 140 . Aberrant expression of miR-21 or other key miRNAs in fibroblasts could, therefore, contribute to their survival and/or differentiation into pathogenic ECM-producing myofibroblasts. Nevertheless, a recent study with miR-21-null mice has raised questions about the overall importance of miR-21 in pathological cardiac remodeling 141 . In rat and mouse studies, miR-192, miR-216a and miR-217 have, like miR-21, been identified as key triggers of fibrosis driven by TGF-β and Smad3 (refs. 142,143) . miR-29 has also been identified in human and mouse studies as a potential therapeutic target in systemic sclerosis, liver fibrosis and cardiac fibrosis [144] [145] [146] . miR-29 seems to promote fibrosis in human cells by directly regulating type I collagen expression 147 . Other miRNAs are constitutively expressed in healthy tissues but are downregulated as fibrosis develops, suggesting that they might have a protective antifibrotic role such as that shown recently for the miRNA let-7d in IPF 148 . Decreases in miR-133 and miR-30 have also been linked to increased activity of connective tissue growth factor (CTGF), which resulted in increased myocardial matrix remodeling 149 . Downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells has been hypothesized to contribute to stellate cell activation and increased ECM production in the liver 150 . Finally, expression of miR-200a has been shown to prevent renal fibrogenesis by repressing TGF-β2 expression 151 . Thus, identifying specific miRNAs that inhibit important fibrogenic pathways or promote tissue healing or regeneration could prove highly beneficial in the treatment of fibrosis 148 . Indeed, the targeting of specific miRNAs with small-molecule inhibitors or miRNA mimics could be a general strategy to treat fibrotic disease.
Key fibrogenic pathways for therapeutic targeting
Mechanistic studies of tissue fibrogenesis have revealed a variety of potential therapeutic approaches to combating progressive fibrotic disease. Some of the unique strategies and targets that have progressed to the clinical-trial phase are discussed briefly in the following sections.
Myofibroblasts and the TGF-β pathway. Because activated myofibroblasts are the key pathogenic cells in all fibrotic diseases, a number of experimental antifibrotic strategies are attempting to target activation, proliferation and/or recruitment of fibroblasts (Box 1 and Table 1 ). Pirfenidone, marketed under the names Esbriet and Pirespa, is the first targeted antifibrotic drug to be approved for the treatment of IPF in Europe and Japan 152 . Although its exact mechanism of action remains unclear, pirfenidone is believed to attenuate fibroblast proliferation and the production by activated myofibroblasts of fibrosis-associated mediators and ECM components. Pirfenidone has also shown efficacy in preclinical models of liver fibrosis, renal fibrosis, hypertrophic cardiomyopathy and radiation-induced fibrosis, suggesting that it may have broad antifibrotic activity. Therapeutic antibodies to TGF-β1 (ref. 153 ), a key cytokine involved in the activation of myofibroblasts; CTGF, a matrix-associated, heparin-binding protein that mirrors the profibrotic activity of TGF-β on fibroblasts; and integrin α v β 6 , which is responsible for the activation of constitutively expressed latent TGF-β 154 , are also being investigated for their antifibrotic activity. A humanized monoclonal antibody to α v β 6 developed by Stromedix and Biogen Idec is being investigated as a treatment for interstitial fibrosis and tubular atrophy in kidney-transplant recipients and as a therapy for IPF 155 . Genzyme (owned by Sanofi-Aventis) is also exploring a humanized pan-TGF-β inhibitor (fresolimumab) as a treatment for patients with early-stage diffuse systemic sclerosis, focal segmental glomerulosclerosis, IPF and myelofibrosis 156, 157 , and antibodies and antisense drugs targeting CTGF are being investigated in IPF and scar-revision surgery 158 . Antagonists of the lysophosphatidic acid-1 receptor, a growth factor that induces CTGF and TGF-β1 expression, are being considered as treatments for kidney fibrosis, IPF and systemic sclerosis 159, 160 . Bone morphogenetic protein-7 has also been identified as a potential therapeutic agent for chronic npg renal injury because it can counteract TGF-β1-induced EMT 161 . An antagonist of the endothelin receptor, which promotes myofibroblast contraction and migration, is being explored in cardiovascular disease and IPF 162 . A humanized monoclonal antibody targeting lysyl oxidase-like-2, an enzyme that catalyzes the cross-linking of collagen, is being explored by Gilead Sciences as a treatment for cardiac fibrosis, IPF and liver fibrosis 163 . Other matrix assembly proteins, such as prolyl hydroxylases, are being investigated preclinically for antifibrotic activity 164 . Bortezomib, a proteasomal inhibitor approved by the US Food and Drug Administration, inhibits TGF-β1 signaling in vitro and has been shown to protect mice from bleomycin-induced skin and lung fibrosis 165 . It also induces apoptosis of hepatic stellate cells 166 . Consequently, bortezomib may prove efficacious for diseases in which TGF-β1, ER stress and activated myofibroblasts have been identified as key pathogenic mediators. Studies are also under way to examine whether a serine/threonine protein kinase inhibitor reduces the number of circulating fibrocytes in individuals with IPF 167 . Because ECM-producing myofibroblasts are the final common pathogenic cell in all fibrotic diseases, any therapy that successfully ablates their activity could have broad antifibrotic activity.
Proinflammatory pathways. Targeting key inflammatory pathways might also prove beneficial in the treatment of fibrosis. Because TNF-α has emerged as a key driver of fibrosis in many experimental studies, clinical trials have been initiated to examine whether inhibitors of the TNF-α pathway could be used to treat IPF and other scarring disorders 29 . Although the small-molecule tyrosine kinase inhibitor imatinib mesylate (Gleevec), which inhibits signaling of PDGF receptor and vascular endothelial growth factor receptor, did not affect survival or lung function in patients with IPF 168 , ongoing trials are investigating its potential as a treatment for nephrogenic systemic fibrosis 169 . Boehringer Ingelheim also has ongoing clinical studies with another investigational tyrosine kinase inhibitor, BIBF 1120, which showed promise in slowing lung-function decline in patients with IPF 170 . Inhibitors of Jaks, a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JakStat pathway, are also being investigated for their therapeutic activity in liver fibrosis and myelofibrosis 171 . Finally, given that recent studies have directly linked IL-17A with TGF-β1 (ref. 61) , therapeutic antibodies that disrupt IL-17 signaling might also prove beneficial for the treatment of fibrosis. Targeting upstream proinflammatory pathways would probably be required in situations in which sustained inflammation is a major driving force in the development of fibrosis. However, it is important to point out that although IFN-γ is a well-known antifibrotic cytokine, IFN-γ1b showed little efficacy in the treatment of IPF or chronic HCV-induced liver fibrosis 172, 173 . Numerous anti-inflammatory drugs, including corticosteroids, immunomodulatory agents and cytotoxic drugs, have also been tested and found to have little to no therapeutic benefit in IPF or other fibrotic diseases, so it remains uncertain whether the newer class of 'anti-inflammatory' drugs will ultimately prove beneficial for fibrosis.
The profibrotic type 2 immune response. The T H 2-associated cytokine IL-13 has emerged as a key driver of infection and allergendriven fibrosis 74, 82, 84 . IL-13 and its receptors have also been detected at high levels in the lungs and blood of patients with IPF 76, 174 . On the basis of these results, Novartis has initiated clinical studies to determine whether humanized IL-13-specific monoclonal antibodies could be used to treat IPF. Sanofi is also exploring the role of type 2 cytokines in IPF using an antibody that targets both IL-4 and IL-13. Support for the potential utility of an IL-13 blocker comes from a recent study in which lebrikizumab, a humanized monoclonal antibody to IL-13 developed by Genentech, was shown to be effective in a subset of adults with poorly controlled asthma 175 . Patients showing the greatest improvement in lung function after lebrikizumab therapy had high pretreatment levels of serum periostin, an
Box 1 Myofibroblasts
During equilibrium, tissue-resident fibroblasts are in a quiescent state, although they are metabolically active and biomechanically support the form and function of the organ they are present in. To repair, regenerate and restore homeostasis after injury, these tissue-resident fibroblasts are activated and transform into myofibroblasts, contractile cells expressing α-SMA and myosin bundles. Myofibroblasts secrete copious amounts of ECM and are vital players in the granulation tissue of the wound, aiding in contracture and closure and orchestrating many aspects of the healing response. Aberrations in the wound-healing program or in other pathological states can summon and sustain myofibroblasts, and several studies have shown that they are an important source of collagens in active fibrotic areas. But evidence is accumulating that, in a variety of tissues, a substantial portion of these profibrotic cells could also arise from regenerating epithelial or endothelial cells or from epithelial stem cell progenitors via EMT or endothelial-mesenchymal transition (EndMT). In some instances, circulating CD34 + bone marrow-derived progenitor cells, termed fibrocytes, have also been shown to be recruited in a CCL2-dependent manner, contributing to the myofibroblast pool at the site of wound repair and fibrosis. Myofibroblast activation, proliferation and survival are mediated by a variety of secreted, soluble and physical factors in the milieu, such as cytokines (IL-1, TNF, TGF-β1 and IL-13), growth factors (CTGF and PDGF) and matrix factors (hyaluronan fragments, mechanical stress and/or stiffness). During normal wound healing, myofibroblasts undergo apoptosis after re-epithelialization of the wound-but the rogue myofibroblasts encountered in fibrotic loci are known to be resistant to programmed cell death. Pathways that elicit and recruit high numbers of myofibroblasts and those that engender resistance to apoptosis are active areas of fibrosis research (see illustration). R x , pathways being targeted for therapy, either preclinically or in clinical trials. IL-13-induced protein 176 . Thus, it will be interesting to determine whether this circulating biomarker could be used to identify individuals with IL-13-dependent fibrosis who might also benefit from anti-IL-13 therapy. Because a growing number of chronic fibrotic diseases are characterized by the excess production of IL-13 and/or increased expression of IL-13-inducible genes, many individuals with fibrosis might benefit from the neutralization of IL-13.
Myeloid cells and T reg cells.
Numerous studies have suggested that macrophages have stage-specific roles in fibrosis 2 . Macrophages show profibrotic activity in the early phases of the wound-healing response by producing inflammatory mediators that can exacerbate tissue injury, such as IL-1β, TNF-α and reactive oxygen and nitrogen species. They also produce profibrotic mediators such as TGF-β1. But in the later stages of the wound-healing response, a subset of macrophages converts into a suppressive phenotype that expresses a variety of anti-inflammatory mediators, such as IL-10, Arg1, programmed death ligand-2 and Relm-α, which promote wound healing and direct the resolution of the inflammatory response 46 . Given the central role that macrophages have in fibrosis, a number of experimental antifibrotic strategies are being designed to regulate the activation and/or recruitment of distinct myeloid-cell populations. For example, Johnson & Johnson is conducting a phase 1 study in individuals with IPF of a human monoclonal antibody to CCL2 (also known as MCP-1), which is involved in the recruitment of inflammatory monocytes 177 .
Researchers at Promedior are investigating the protective effects of recombinant human serum amyloid P (SAP; also known as pentraxin 2) in IPF and post-surgical scarring in patients treated for glaucoma 178 . Their preclinical studies have suggested that SAP reduces inflammation and fibrosis by inducing the production of IL-10 in 'proresolution' macrophages 179 . Ono Pharmaceutical is examining whether a competitive inhibitor of human neutrophil elastase would ImmuneWorks investigators are examining whether an orally administered antigen will induce oral tolerance by expanding a population of collagen type V-specific T reg cells 104 . Thus, therapies that modulate the activation and/or recruitment of T reg cells or distinct macrophage populations could emerge as viable treatments for fibrotic disease. These strategies are particularly attractive because they are based on alteration of the character of the immune response rather than simple disruption of it, which could have a more durable antifibrotic effect.
Conclusions and future directions
There are many distinct immunological and molecular mechanisms that can contribute to the progression of fibrotic disease. Dysregulated innate and adaptive immune responses are major contributors to fibrosis. However, cell-intrinsic modifications in fibroblasts and other structural cells can also contribute to fibrosis and should be considered in the design and testing of new antifibrotic therapies. Because fibrosis is often characterized by the activation of several profibrotic pathways, a multipronged approach will probably be needed to slow the progression of fibrosis. Therapeutics that target key epigenetic modifications or miRNAs could emerge as viable strategies because they regulate large families of genes rather than a single target. However, a more integrated antifibrotic strategy that simultaneously targets important inflammatory mediators, profibrotic cytokines and epigenetic and cell and/or tissue intrinsic changes will probably emerge as the most successful way to treat this highly complex and difficult-to-manage pathology. Thus, we need to begin devising and testing strategies that incorporate combination therapies. One of the major obstacles slowing the development of antifibrotic drugs is the lack of diseasespecific biomarkers that can be used to identify patients who might benefit from a specific therapy. Therefore, it will be important to incorporate genetic and biological phenotyping in the clinical staging of patients diagnosed with fibrosis, so that more homogenous patient populations can be selected for specific trials. It will also be important to design clinical trials with well-defined clinical endpoints and to develop techniques that can quickly, noninvasively and accurately evaluate the efficacy of new antifibrotic therapies. Examples of such techniques are the 6-minute walk test, measurements of forced vital capacity and patient-recorded outcomes (such as dyspnea and quality-of-life changes) used in some IPF trials. New and improved preclinical models that more closely replicate fibrotic diseases in humans are also needed, as was recently demonstrated in a mouse model of liver cirrhosis 92 . Studies are increasingly suggesting that, although fibrosis is often linked with a strong inflammatory response initially, there are specific mediators and pathways contributing to the pathogenesis of fibrosis that are distinct from the mechanisms driving inflammation. Thus, to design effective therapeutics for fibrotic disease, we need to begin viewing fibrosis as a pathological process distinct from inflammation. Further, because inflammatory mediators are intimately involved in wound repair and regulate both the initiation and resolution of fibrosis, we need to figure out how to harness the beneficial aspects of inflammation so that fibrosis can be slowed or reversed and normal tissue regenerated, which is the ultimate goal of all fibrosis research.
